Drug interactions
Buprenorphine subdermal implant + Dasatinib
Severity: Moderate
Buprenorphine subdermal implant and Dasatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both drugs have QT-prolonging potential. Buprenorphine from the implant is released continuously at low plasma levels, so the added arrhythmic risk is probably small but may matter in patients with other risk factors.
What this interaction means in plain words
Buprenorphine subdermal implant and Dasatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Additive QT prolongation.
What to do
Obtain a baseline ECG in patients with cardiac risk factors and monitor the QTc and electrolytes while both are used. Avoid adding further QT-prolonging drugs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Buprenorphine subdermal implant and Dasatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Dasatinib
- Dasatinib + Saquinavir Contraindicated
- Dasatinib + Thioridazine Contraindicated
- Adagrasib + Dasatinib Major
- Amiodarone + Dasatinib Major
- Amisulpride + Dasatinib Major
- Amitriptyline + Dasatinib Major
Frequently asked questions
Can I take Buprenorphine subdermal implant with Dasatinib?
MediHelp rates the interaction as moderate. Buprenorphine subdermal implant and Dasatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Both drugs have QT-prolonging potential. Buprenorphine from the implant is released continuously at low plasma levels, so the added arrhythmic risk is probably small but may matter in patients with other risk factors.
How serious is the interaction between Buprenorphine subdermal implant and Dasatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain a baseline ECG in patients with cardiac risk factors and monitor the QTc and electrolytes while both are used. Avoid adding further QT-prolonging drugs.
What other medicines interact with Dasatinib?
MediHelp also lists interactions of Dasatinib with, for example, Saquinavir, Thioridazine, Adagrasib. The full list is on the Dasatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
